Cai Jing Wang·2025-09-17 11:29Core Viewpoint - The core issue revolves around Jiang Wei, a significant shareholder and actual controller of Hyaluronic Acid giant Haohai Biological Technology, receiving a notice of administrative penalty from the China Securities Regulatory Commission for suspected insider trading. The company asserts that the matter is unrelated to its operations and is solely a personal issue concerning Jiang Wei [1]. Company Summary - Haohai Biological Technology announced that Jiang Wei, one of its major shareholders and actual controllers, has been penalized by the China Securities Regulatory Commission for alleged insider trading [1]. - The company emphasized that the penalty pertains to Jiang Wei as an individual and does not involve the company itself [1]. - Although Jiang Wei founded Haohai Biological Technology, he has largely remained behind the scenes and does not actively participate in the company's operations [1]. - Jiang Wei has established a shareholding structure that allows him to maintain control over Haohai Biological Technology, and he has received over 250 million yuan in dividends from the company during its six years as a publicly listed entity [1]. Industry Context - The incident highlights the ongoing scrutiny of insider trading practices within the biotechnology sector in China, particularly among companies with significant market presence like Haohai Biological Technology [1]. - The company's chairman, Hou Yongtai, previously stated that Jiang Wei is primarily an investor who enjoys trading stocks, but he does not engage in trading Haohai Biological Technology's shares [1].